Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29731083 | 1.00 | TSHR (0.64) | TSHRNPSR1MAPKAPK2DRD2DRD1 | |
| SCHEMBL4573507 | 0.89 | TSHR (0.62) | TSHRNPSR1MAPKAPK2DRD2DRD1 | |
| SCHEMBL15605763 | 0.82 | TSHR (0.62) | TSHRNPSR1MAPKAPK2KDM1A | |
| SCHEMBL7202686 | 0.82 | TSHR (0.62) | TSHRNPSR1MAPKAPK2DRD1KDM1A | |
| SCHEMBL4491436 | 0.81 | MAPKAPK2 (0.46) | TSHRNPSR1MAPKAPK2DRD2DRD1 | |
| SCHEMBL574702 | 0.79 | TSHR (0.97) | TSHRNPSR1MAPKAPK2 | |
| SCHEMBL29505877 | 0.79 | TSHR (0.97) | TSHRNPSR1MAPKAPK2 | |
| SCHEMBL29381539 | 0.79 | TSHR (0.97) | TSHRNPSR1MAPKAPK2 | |
| SCHEMBL29597389 | 0.79 | TSHR (0.97) | TSHRNPSR1MAPKAPK2 | |
| SCHEMBL514422 | 0.79 | TSHR (0.97) | TSHRNPSR1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883721-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | MCGILL UNIVERSITY (CA) | 2014-11-11 | — | — | US | claimed |
| WO-2013142229-A1 | DESIGNING NOVEL PEPTIDES FOR INDUCING FIBRONECTIN MATRIX ASSEMBLY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-09-26 | — | — | WO | claimed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | claimed |
| WO-2011126882-A2 | THERAPEUTIC PEPTIDES AND THEIR DERIVATIVES AND THERAPEUTIC USES THEREOF | AMERICAN TYPE CULTURE COLLECTION (US) | 2011-10-13 | — | — | WO | claimed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | claimed |
| US-20060148714-A1 | Therapeutic peptide-based constructs | LITTLE ROGER G II | 2006-07-06 | — | — | US | claimed |
| US-6964948-B2 | Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein | XOMA TECHNOLOGY LTD. (BM) | 2005-11-15 | — | — | US | claimed |
| US-6906037-B2 | Therapeutic peptide-based constructs | XOMA TECHNOLOGY LTD. (BM) | 2005-06-14 | — | — | US | claimed |
| US-20040048793-A1 | Therapeutic peptide-based constructs | LITTLE ROGER G (US) | 2004-03-11 | — | — | US | claimed |
| US-20030144195-A1 | Therapeutic peptide-based constructs | LITTLE ROGER G (US) | 2003-07-31 | — | — | US | claimed |
| US-6515104-B1 | 8-15 amino acid moieties having heparin neutralization and binding and inhibiting endothelial cell proliferation and/or angiogenesis; diagnotic applications | XOMA TECHNOLOGY LTD. (BM) | 2003-02-04 | — | — | US | claimed |
| US-6423825-B1 | OCTA-, NONA-, DECA- OR POLYPEPTIDE; HEPARIN BINDING AND NEUTRALIZATION; ANTIPROLIFERATIVE AGENTS OF ENDOTHELIAL CELLS; ANGIOGENESIS INHIBITORS | XOMA TECHNOLOGY LTD. (BM) | 2002-07-23 | — | — | US | claimed |
| EP-1196440-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA Technology Ltd. (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2001000655-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | claimed |
| EP-4748438-A2 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | Cedars-Sinai Medical Center (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137751-A1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | CEDARS-SINAI MEDICAL CENTER (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-1196440-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA Technology Ltd. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000655-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000671-A1 | DERIVATIVE COMPOUNDS | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | TSHR 27/4885NPSR1 114/4885MAPKAPK2 2840/4885 |
| US-20060148714-A1 | Therapeutic peptide-based constructs | SPPL2B, LNPEP, VIP | TSHR 2355/4885NPSR1 2496/4885MAPKAPK2 2522/4885 |
| US-20030144195-A1 | Therapeutic peptide-based constructs | LNPEP, SPPL2B, ENPEP | TSHR 2933/4885NPSR1 2684/4885MAPKAPK2 2729/4885 |
| US-20260137751-A1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | GLP1R, GIPR, NPY2R | TSHR 87/4885NPSR1 469/4885MAPKAPK2 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.